QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hasinoff, B. B. Articles by Patel, D. Search for Related Content PubMed PubMed Citation Articles by Hasinoff, B. B. Articles by Patel, D.

The Metabolites of the Cardioprotective Drug Dexrazoxane Do Not Protect Myocytes from Doxorubicin-Induced Cytotoxicity

Faculty of Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada

The clinically approved cardioprotective agent dexrazoxane (ICRF-187) and two of its hydrolyzed metabolites (a one-ring open form of dexrazoxane and ADR-925) were examined for their ability to protect neonatal rat cardiac myocytes from doxorubicin-induced damage. Dexrazoxane may protect against doxorubicin-induced damage to myocytes through its strongly metal-chelating hydrolysis product ADR-925, which could act by displacing iron bound to doxorubicin or chelating free or loosely bound iron, thus preventing site-specific iron-based oxygen radical damage. The results of this study showed that whereas dexrazoxane was able to protect myocytes from doxorubicin-induced lactate dehydrogenase release, neither of the metabolites displayed any protective ability. Dexrazoxane also reduced apoptosis in doxorubicin-treated myocytes. The ability of dexrazoxane and its three metabolites to displace iron from a fluorescence-quenched trapped intracellular iron-calcein complex was also determined to see whether the metabolites were taken up by myocytes. Although ADR-925 was taken up in the absence of calcium in the medium, in the presence of calcium, its uptake was greatly slowed, presumably because it formed a complex with calcium. Both of the one-ring open metabolites were taken up by myocytes and displaced iron from its complex with calcein. These results suggest either that the anionic metabolites do not have the same access to iron pools in critical cellular compartments, that their uptake is slowed in the presence of calcium, or, less likely, that dexrazoxane protects by some other mechanism.

Address correspondence to: Dr. Brian Hasinoff, Faculty of Pharmacy, University of Manitoba, Winnipeg, Manitoba R3T 2N2 Canada. E-mail: B_Hasinoff{at}UManitoba.ca

This article has been cited by other articles:

				P. E. Schroeder, D. Patel, and B. B. Hasinoff The Dihydroorotase Inhibitor 5-Aminoorotic Acid Inhibits the Metabolism in the Rat of the Cardioprotective Drug Dexrazoxane and Its One-Ring Open Metabolites Drug Metab. Dispos., September 1, 2008; 36(9): 1780 - 1785. [Abstract] [Full Text] [PDF]

				M. Grauslund, A. V. Thougaard, A. Fuchtbauer, K. F. Hofland, P. H. Hjorth, P. B. Jensen, M. Sehested, E.-M. Fuchtbauer, and L. H. Jensen A Mouse Model for Studying the Interaction of Bisdioxopiperazines with Topoisomerase II{alpha} in Vivo Mol. Pharmacol., October 1, 2007; 72(4): 1003 - 1014. [Abstract] [Full Text] [PDF]

				P. E. Schroeder and B. B. Hasinoff METABOLISM OF THE ONE-RING OPEN METABOLITES OF THE CARDIOPROTECTIVE DRUG DEXRAZOXANE TO ITS ACTIVE METAL-CHELATING FORM IN THE RAT Drug Metab. Dispos., September 1, 2005; 33(9): 1367 - 1372. [Abstract] [Full Text] [PDF]

				P. E. Schroeder, G.-Q. Wang, F. J. Burczynski, and B. B. Hasinoff METABOLISM OF THE CARDIOPROTECTIVE DRUG DEXRAZOXANE AND ONE OF ITS METABOLITES BY ISOLATED RAT MYOCYTES, HEPATOCYTES, AND BLOOD Drug Metab. Dispos., June 1, 2005; 33(6): 719 - 725. [Abstract] [Full Text] [PDF]

				G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229. [Abstract] [Full Text] [PDF]